Non‐psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE: Two non‐psychoactive cannabinoids, cannabidiol (CBD) and cannabichromene (CBC), are known to modulate in vitro the activity of proteins involved in nociceptive mechanisms, including transient receptor potential (TRP) channels of vanilloid type‐1 (TRPV1) and of ankyrin type‐1 (TRPA1), the equilibrative nucleoside transporter and proteins facilitating endocannabinoid inactivation. Here we have tested these two cannabinoids on the activity of the descending pathway of antinociception. EXPERIMENTAL APPROACH: Electrical activity of ON and OFF neurons of the rostral ventromedial medulla in anaesthetized rats was recorded extracellularly and tail flick latencies to thermal stimuli were measured. CBD or CBC along with various antagonists were injected into the ventrolateral periaqueductal grey. KEY RESULTS: Cannabidiol and CBC dose‐dependently reduced the ongoing activity of ON and OFF neurons in anaesthetized rats, whilst inducing antinociceptive responses in the tail flick‐test. These effects were maximal with 3 nmol CBD and 6 nmol CBC, and were antagonized by selective antagonists of cannabinoid CB 1 adenosine A 1 and TRPA1, but not of TRPV1, receptors. Both CBC and CBD also significantly elevated endocannabinoid levels in the ventrolateral periaqueductal grey. A specific agonist at TRPA1 channels and a synthetic inhibitor of endocannabinoid cellular reuptake exerted effects similar to those of CBC and CBD. CONCLUSIONS AND IMPLICATIONS: CBD and CBC stimulated descending pathways of antinociception and caused analgesia by interacting with several target proteins involved in nociceptive control. These compounds might represent useful therapeutic agents with multiple mechanisms of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Endogenous Pain Control Systems: Brainstem Spinal Pathways and Endorphin Circuitry
Basbaum, A. I., & Fields, H. L. (1984) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.07.030184.001521 · Cited by 2,687
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 2×
“…with a rotating evaporator, and aliquots were analysed by isotope dilution-liquid chromatography/ atmospheric pressure chemical ionization/mass spectrometry (LC-APCI-MS) carried out under conditions described previously (Marsicano et al., 2002) and allowing the separation of the four compounds.”
MethodModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 5×
“Clearly, CBD is a much less potent FAAH inhibitor than URB597 (Bisogno et al., 2001; Kathuria et al., 2003), thus possibly explaining why this compound, in terms of its differential effect on the levels of the two endocannabinoids, seemed to be acting in this study more as a weak endocannabinoid…”
BackgroundInfluentialState-dependent opioid control of pain
Fields, H. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1431 · Cited by 946 · cited 4×
“and adenosine A1 receptor agonists, have been found to reduce ON cell and stimulate OFF cell activity after intra-PAG injections (Fields et al., 1983; Heinricher and Tortorici, 1994; Meng et al., 1998; Fields, 2004; de Novellis et al., 2005; Maione et al., 2007).”
BackgroundInfluentialFunctional characteristics of the midbrain periaqueductal gray.
Behbehani, M. M. (1995) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00009-k · Cited by 879
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878 · cited 4×
“…of adenosine signalling and associated pharmacological actions, including analgesia and inhibition of inflammation; and (iv) the 5-HT1A receptor (Russo et al., 2005; Campos and Guimarães, 2008; Resstel et al., 2009; Magen et al., 2010; Zanelati et al., 2010), which has been implicated in the…”
BackgroundInfluentialMechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515 · cited 1×
“…(THC) and cannabidiol (CBD), are known to possess strong analgesic and anti-inflammatory properties and their clinical use is now supported by several preclinical studies and clinical trials (see Mechoulam et al., 2007; Karst and Wippermann, 2009; Rahn and Hohmann, 2009; for reviews).”
BackgroundCarrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511232103 · Cited by 497 · cited 5×
“This finding is in agreement with previous evidence indicating that CBD can produce several pharmacological effects via inhibition of the equilibrative nucleoside transporters (Carrier et al., 2006), and subsequent enhancement of adenosine tone at the various adenosine receptors (Liou et al.”
BackgroundResultInfluentialAn analgesia circuit activated by cannabinoids
Meng, I. D., Manning, B. H., Martin, W. J., & Fields, H. L. (1998) · Nature · doi:10.1038/26481 · Cited by 411 · cited 4×
“and adenosine A1 receptor agonists, have been found to reduce ON cell and stimulate OFF cell activity after intra-PAG injections (Fields et al., 1983; Heinricher and Tortorici, 1994; Meng et al., 1998; Fields, 2004; de Novellis et al., 2005; Maione et al., 2007).”
BackgroundInfluentialCampos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364 · cited 4×
“, 2006), thereby causing elevation of adenosine signalling and associated pharmacological actions, including analgesia and inhibition of inflammation; and (iv) the 5-HT1A receptor (Russo et al., 2005; Campos and Guimarães, 2008; Resstel et al., 2009; Magen et al., 2010; Zanelati et al., 2010), which has been implicate…”
BackgroundInfluentialCannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305 · cited 1×
“…(THC) and cannabidiol (CBD), are known to possess strong analgesic and anti-inflammatory properties and their clinical use is now supported by several preclinical studies and clinical trials (see Mechoulam et al., 2007; Karst and Wippermann, 2009; Rahn and Hohmann, 2009; for reviews).”
BackgroundResstel, L. B. M., Tavares, R. F., Lisboa, S. F. S., Joca, S. R. L., Corrêa, F. M. A., & Guimarães, F. S. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00046.x · Cited by 283 · cited 4×
“…actions, including analgesia and inhibition of inflammation; and (iv) the 5-HT1A receptor (Russo et al., 2005; Campos and Guimarães, 2008; Resstel et al., 2009; Magen et al., 2010; Zanelati et al., 2010), which has been implicated in the descending modulation of nociception (Kishimoto…”
BackgroundInfluentialCastillo, A., Tolón, M. R., Fernández-Ruiz, J., Romero, J., & Martinez-Orgado, J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.10.023 · Cited by 279
Bisogno, T., Petrocellis, L., & Marzo, V. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023395655 · Cited by 112 · cited 1×
“…elevated both anandamide and 2-AG levels, because both endocannabinoids are good substrates for the putative membrane endocannabinoid transporter (Bisogno et al., 2002), whereas FAAH inhibition was previously shown to elevate anandamide but not 2-AG levels in the whole brain (Kathuria et al.,…”
BackgroundSelf-citation
Cited by
Molecular Targets of Cannabidiol in Neurological Disorders
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 578
The draft genome and transcriptome of Cannabis sativa.
van Bakel, H., Stout, J. M., Cote, A. G., Tallon, C. M., Sharpe, A. G., Hughes, T. R., & Page, J. E. (2011) · Genome Biology · doi:10.1186/gb-2011-12-10-r102 · Cited by 575
“For example, analysis of the PK transcriptome has enabled us to identify several candidate genes that might encode CBCAS, which forms a cannabinoid with interesting biological activities [14,52,53].”
BackgroundMcPartland, J. M., Duncan, M., Di Marzo, V., & Pertwee, R. G. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12944 · Cited by 521
Self-citationNew approaches and challenges to targeting the endocannabinoid system
Di Marzo, V. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.115 · Cited by 480
Self-citationLigresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Self-citation
Metadata
- Authors
- Maione, S., Piscitelli, F., Gatta, L., Vita, D., De Petrocellis, L., Palazzo, E., de Novellis, V., & Di Marzo, V.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-01-12
- Volume
- 162
- Issue
- 3
- Pages
- 584-596
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1568755291
- Cited by
- 175
- References
- 16
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.